Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population.

Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Poggio PD, Rapaccini G, Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Pinna AD; Italian Liver Cancer (ITA.LI.CA) Group.

J Hepatol. 2012 May;56(5):1089-96. doi: 10.1016/j.jhep.2011.11.022. Epub 2012 Jan 13.

PMID:
22245900
2.

Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region.

Amarapurkar D, Han KH, Chan HL, Ueno Y; Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma.

J Gastroenterol Hepatol. 2009 Jun;24(6):955-61. doi: 10.1111/j.1440-1746.2009.05805.x. Epub 2009 Mar 11.

PMID:
19383082
3.

Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population.

Cucchetti A, Piscaglia F, Caturelli E, Benvegnù L, Vivarelli M, Ercolani G, Cescon M, Ravaioli M, Grazi GL, Bolondi L, Pinna AD.

Ann Surg Oncol. 2009 Feb;16(2):413-22. doi: 10.1245/s10434-008-0232-4. Epub 2008 Nov 26.

PMID:
19034578
4.

Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances.

Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H, Nakamura S, Kobayashi Y, Araki Y, Aoki N, Shiratori Y.

J Gastroenterol Hepatol. 2008 Mar;23(3):437-44. Epub 2007 Aug 6.

PMID:
17683496
5.

Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.

Robotin MC, Kansil M, Howard K, George J, Tipper S, Dore GJ, Levy M, Penman AG.

J Hepatol. 2009 May;50(5):990-8. doi: 10.1016/j.jhep.2008.12.022. Epub 2009 Feb 15.

PMID:
19303657
6.

High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity.

Donato MF, Arosio E, Del Ninno E, Ronchi G, Lampertico P, Morabito A, Balestrieri MR, Colombo M.

Hepatology. 2001 Sep;34(3):523-8.

PMID:
11526538
7.

Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.

Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, Lobello S, Farinati F, Naccarato R.

Cancer. 1999 May 15;85(10):2132-7.

PMID:
10326690
8.

Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.

Lin OS, Keeffe EB, Sanders GD, Owens DK.

Aliment Pharmacol Ther. 2004 Jun 1;19(11):1159-72.

9.

Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.

Sangmala P, Chaikledkaew U, Tanwandee T, Pongchareonsuk P.

Asian Pac J Cancer Prev. 2014;15(20):8993-9004.

10.

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M.

Gut. 2001 Feb;48(2):251-9.

11.

Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival.

Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, Di Nolfo MA, Benvegnù L, Farinati F, Zoli M, Giannini EG, Borzio F, Caturelli E, Chiaramonte M, Bernardi M; Italian Liver Cancer (ITA.LI.CA) Group.

J Hepatol. 2010 Aug;53(2):291-7. doi: 10.1016/j.jhep.2010.03.010. Epub 2010 Apr 27.

PMID:
20483497
12.

Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups.

Mancebo A, González-Diéguez ML, Cadahía V, Varela M, Pérez R, Navascués CA, Sotorríos NG, Martínez M, Rodrigo L, Rodríguez M.

Clin Gastroenterol Hepatol. 2013 Jan;11(1):95-101. doi: 10.1016/j.cgh.2012.09.007. Epub 2012 Sep 13.

PMID:
22982095
13.

The risk of hepatocellular carcinoma in cirrhotic patients with small liver nodules on MRI.

Shah TU, Semelka RC, Pamuklar E, Firat Z, Gerber RD, Shrestha R, Russo MW.

Am J Gastroenterol. 2006 Mar;101(3):533-40.

PMID:
16542290
14.

[Screening for the early diagnosis of hepatocellular carcinoma: cost-effectiveness analysis].

Bolondi L, Gaiani S, Casali A, Serra C, Piscaglia F.

Radiol Med. 1997 Jul-Aug;94(1-2):4-7. Italian.

PMID:
9424649
15.

Hepatocellular carcinoma in patients without cirrhosis in Italy.

Giannini EG, Marenco S, Bruzzone L, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F.

Dig Liver Dis. 2013 Feb;45(2):164-9. doi: 10.1016/j.dld.2012.08.018. Epub 2012 Oct 7.

PMID:
23047000
16.

In whom, how and how often is surveillance for hepatocellular carcinoma cost-effective?

Ruelas-Villavicencio AL, Vargas-Vorácková F.

Ann Hepatol. 2004 Oct-Dec;3(4):152-9.

PMID:
15657557
17.

Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis?

Giannini E, Arzani L, Borro P, Botta F, Fasoli A, Risso D, Celle G, Testa R.

Hepatogastroenterology. 2000 Sep-Oct;47(35):1395-8.

PMID:
11100360
18.

Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.

Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, De Franchis R, Colombo M.

Gastroenterology. 2004 Apr;126(4):1005-14.

PMID:
15057740
19.

Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.

Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK; HEPNET. Greece Cohort Study Group.

Gut. 2011 Aug;60(8):1109-16. doi: 10.1136/gut.2010.221846. Epub 2011 Jan 26.

PMID:
21270118
20.

Delay in treatment of early-stage hepatocellular carcinoma using radiofrequency ablation may impact survival of cirrhotic patients in a surveillance program.

Chen WT, Fernandes ML, Lin CC, Lin SM.

J Surg Oncol. 2011 Feb;103(2):133-9. doi: 10.1002/jso.21797. Epub 2010 Dec 7.

PMID:
21259246

Supplemental Content

Support Center